Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval.

× No keyword cloud information.

5 in total

1. The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?

Authors: Mark P Lythgoe; Vinay Prasad
Journal: Nat Rev Clin Oncol Date: 2021-12 Impact factor: 66.675

2. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.

Authors: Mark P Lythgoe; Aakash Desai; Bishal Gyawali; Philip Savage; Jonathan Krell; Jeremy L Warner; Ali Raza Khaki
Journal: JAMA Netw Open Date: 2022-06-01

3. Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?

Authors: A Haslam; T Olivier; R Thawani; V Prasad
Journal: ESMO Open Date: 2022-04-22

4. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.

Authors: Cheryl Ho; Howard J Lim; Dean A Regier
Journal: Curr Oncol Date: 2022-01-18 Impact factor: 3.677

5. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.

Authors: Timothée Olivier; Vinay Prasad
Journal: Transl Oncol Date: 2022-02-20 Impact factor: 4.243

5 in total